CELGENE CORPORATION

The nanomedicine market, valued at USD 223.6 billion in 2023, is projected to reach USD 634.2 billion by 2032, driven by advanced drug delivery systems and rising chronic diseases. Key players include Johnson & Johnson, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries. Recent developments include Novartis's nanoparticle-based ovarian cancer treatment and Merck's partnership with Stanford for immunotherapy research.

Former Pfizer executives Ian Read and Frank D’Amelio decline to support Starboard Value’s efforts to reform Pfizer, citing support for current management. Starboard alleges coercion by Pfizer, which denies the claim. Starboard, with a $1 billion stake in Pfizer, seeks changes to boost profitability, criticizing excessive spending on acquisitions post-COVID-19 vaccine success. Pfizer faces challenges including falling vaccine sales, missed opportunities in obesity drugs, and patent expirations.

FDA grants Biogen's monoclonal antibody felzartamab breakthrough therapy designation for treating late antibody-mediated rejection in kidney transplant patients, based on positive Phase II trial data. Biogen plans to initiate Phase III trials for felzartamab in multiple indications next year. The therapy, acquired through the $1.15bn HI-Bio acquisition, is expected to generate over $776m by 2032 if approved.

The Red Biotechnology Market is projected to grow at a CAGR of 5.2% by 2031, driven by advancements in pharmaceuticals, vaccines, and diagnostics. Key players include Hoffmann-La Roche, Ltd., Merck KGaA, and Regeneron Pharmaceuticals, Inc. The market is segmented by product type, application, and end user, with regional focus on North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Bristol Myers Squibb won dismissal of a $6.4 billion lawsuit claiming it delayed FDA approval for Breyanzi and two other drugs, as Judge Jesse Furman ruled UMB Bank was not properly appointed trustee for Celgene shareholders' contingent value rights (CVR).

MP Nigdelis received honoraria from RG Ärztefortbildung GmbH and travel grants from Organon and Gedeon Richter. M Doerk received travel grants from Gedeon Richter, Organon, and Eisai, and is a member of DGGG, AGE, and Deutsche Gesellschaft für Senologie. S Burghaus received honoraria from FOMF and is a member of DGGG, AGEM, AGE, Stiftung Endometriose Forschung, AGUB, AGO, and DKK. M Sillem, CEO of EuroEndoCert Gmbh, received payments from Bayer, Gedeon Richter, Hologic, and EndoHealth. B Haj Hamoud received travel grants from Gedeon Richter, Astrazeneca, Johnson & Johnson, and Storz, and is a member of DGGG, AGE, and Stiftung Endometriose Forschung. EF Solomayer receives grants from the University of Saarland, Storz, and Erbe, and fees from Roche, Pfizer, Celgene, Amgen, Astra Zeneca, Esai, Johnson & Johnson, Novartis, Tesaro, Teva, Medac GmbH, MSD, Vifor, Gedeon Richter, Takeda, and AGE, among others. GL Olmes received grants from AstraZeneca, Universitätsklinikum Freiburg, and RG Ärztefortbildung GmbH, and is a member of DGGG, AGE, and AGEM, with scientific collaboration with Karl Stotz.

Epigenetic drugs' Series A venture financing doubled, reaching $342m YTD 2024. Moonwalk Biosciences raised $57m in Jan 2024. Marketed drugs like DNMT and HDAC inhibitors show success in blood cancers but have off-target effects. New generation drugs aim for improved specificity. FDA's approval of Vertex's Casgevy in Dec 2023 boosted investor confidence. Avenzo Therapeutics raised $150m in Mar 2024 for CDK2 inhibitor ARTS-021. Challenges include durable gene expression effects and drug delivery.

Savara Inc. appoints Braden Parker as Chief Commercial Officer to oversee global strategy for molgramostim in aPAP, with a potential BLA submission to the FDA in H1 2025.

VerImmune Inc. secures $4.5 million in Pre-Series A funding led by Beiley Biofund, with participation from Dr. John Ballantyne and others. The funds will advance the ViP-based therapeutics platform, including the lead product VERI-101, a first-in-class cancer immunotherapy. The company also adds Dr. Che Hsu and Dr. Marta New to its Board of Directors.